Prior Auth Required

60015 - 4 Zolgensma Prescribing Information, AveXis, Inc., Bannockburn, IL . 2/2025 8/2025

This procedure appears on the selected insurer prior authorization source.

Check another codeExplore policy data
Prior authorizationPrior Auth Required
Procedure / Service4 Zolgensma Prescribing Information, AveXis, Inc., Bannockburn, IL . 2/2025 8/2025
Procedure / Service Description

2 Rao VK, Kapp D, Schroth M. Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a 2018 7/2022 - 3 Institute for Clinical and Economic Review (ICER). Sprinaza and Zolgensma for Spinal Muscular Atrophy: 4/2019 7/2022 Effectiveness and Value. Final Evidence Report. 2019 Apr 3. Accessed 7/22 4 Zolgensma Prescribing Information, AveXis, Inc., Bannockburn, IL 60015. 2/2025 8/2025 5 Butchbach ME. Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal 7/2022 7/2022 Muscular Atrophy and Other Neurodegenerative Diseases. Front Mol Biosci 2016; 3:7. Copyright © 2016

Likely documents
  • Confirm benefit details
  • Submit clinical notes if requested by the plan
Next actions
  • Confirm the current plan policy before submission.
  • Use the insurer authorization workflow for this listed code.